Preparation and Analysis of Lyophilization Characterization of Human D-dimer

Abstract

Abstract: D-dimer is formed by sequential action of 3 enzymes from fibrinogen. After producing D-dimer, we did the research on its lyophilization process. To produce cross-linked fibrin, fibrinogen was digested by thrombin and Factor XIIa. Then, fibrin degradation products（FDP）was prepared from cross-linked fibrin being degraded by plasmin. D-dimer was purified from FDP through ultrafiltration and prepared into lyophilized powder. By optimizing the lyophilization program, lyophilized D-dimer was stable for at least 12 days at 37℃, stable for at least 8 days at 25℃ and 30 days at 4℃ after reconstitution, and not different when being dissolved by different solvent.The preparation system established in this research is feasible and efficient. Depend on its stability, lyophilized D-dimer could be provided as biological raw materials for further research.

Key words: Fibrin , Fibrinogen , D-dimer, Thrombus , Lyophilized power

Wu Jianwei ,Cai Lei ,Wang Jihua, Tang Shixing. Preparation and Analysis of Lyophilization Characterization of Human D-dimer[J]. Biotechnology Bulletin, 2014, 0(11): 219-224.

References

[1]Soheir SA, Nigel SK, Charles SG. D-dimer antigen：current concepts and future prospects[J]. Blood, 2009, 113（13）：2878-2887.
[2]Michael WM, Kevin RS, David AM. The structure and biological features of fibrinogen and fibrin[J]. Annals of the New York Academy of Sciences, 2001, 936（1）：11-30.
[3]Dempfle CE, Mosesson MW. Theme issue：fibrinogen and fibrin--structure, function, interactions and clinical applications[J]. Thrombosis and Haemostasis, 2003, 89（4）：599-600.
[4]Reganon E, Aznar J, Vila V. Degradation of human fibrinogen by plasmin：A kinetic study[J]. Thrombosis Research, 1977, 10（3）：411-419.
[5]Francis CW, Marder VJ, Martin SE. Plasmic degradation of crosslinked fibrin. I. Structural analysis of the particulate clot and identification of new macromolecular-soluble complexes[J]. Blood, 1980, 56（3）：456-464.
[6]Tsuneaki S, Motoaki S, Satoshi O. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during ora anticoagulant therapy[J]. J Am Coll Cardiol, 2010, 55（20）：2225-2231.
[7]Renee AD, Melanie T, Roger EG, et al. Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded[J]. Haematol, 2012, 97（10）：1507-1513.
[8]Bastos RD, Bogutchi T, Rezende SM, et al. Duration of symptoms and D-dimer testing in the ruling-out of venous thromboembolism[J]. J Thrombosis and Haemostasis, 2006, 4（9）：2079-2080.
[9]Wells PS. Integrated strategies for the diagnosis of venous thromboembolism[J]. J Thrombosis and Haemostasis, 2007, 5（1）：41-50.
[10]Wells PS, Anderson DR, Rodger M, et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis[J]. N Engl J Med, 2003, 349（13）：1227-1235.
[11]Carr JM, McKinney M, McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer[J]. American Journal of Clinical Pathology, 1989, 91（3）：280-287.
[12]Lawler CM, Bovill EG, Collen DJ, et al. Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction[J]. Blood, 1990, 76（7）：1341-1348.
[13]Bayes-Genis A, Mateo J, Santalo M, et al. D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain[J]. American Heart Journal, 2000, 140（3）：379-384.
[14]Dougu N, Takashima S, Sasahara E, et al. Differential diagnosis of cerebral infarction using an algorithm combining atrial fibrillation and D-dimer level[J]. European Journal of Neurology, 2008, 15（3）：295-300.
[15]Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer[J]. Lung Cancer, 2006, 53（2）：205-210.
[16]Mirshahi SS, Pujade-Lauraine E, Soria C, et al. D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy prognostic significance for the success of anti-cancer treatment[J]. Cancer, 1992, 69（9）：2289-2292.
[17]Oya M, Akiyama Y, Yanagida T, et al. Plasma D-dimer level in patients with colorectal cancer：Its role as a tumor marker[J]. Surg Today, 1998, 28（4）：373-378.
[18]Sutherland DE, Weitz IC, Liebman HA. Thromboembolic complications of cancer：epidemiology, pathogenesis, diagnosis, and treatment[J]. American Journal of Hematology, 2003, 72（1）：43-52.
[19]Roberts LN, Patal RK, Arya R. Haemostasis and thrombosis in liver disease[J]. British Journal of Haematology, 2009, 148（4）：507-521.
[20]Ceriello A, Taboga C, Giacomello R, et al. Fibrinogen plasma levels as a marker of thrombin activation in diabetes[J]. Diabetes, 1994, 43（3）：430-432.
[21]Zhou HY, Chen R, Liu XP, et al. Determination of plasma D dimer in patients with pregnancy induced hypertension[J]. Chinese Journal of Obstetrics and Gynecology, 1997, 32（6）：347-349.
[22]Przic DS, Ruzic NL, Petrovic SD. Lyophilization-the process and industrial use[J]. Hemijska Industrija, 2004, 58（12）：552-562.
[23]Ruckley CV, Das PC, Leitch AG, et al. Serum fibrin/fibrinogen degradation products associated with postoperative pulmonary embolus and venous thrombosis[J]. Br Med J, 1970, 4（5732）：395-398.
[24]Gaffney PJ, Brasher M. Subunit structure of the plasmin-induced degradation products of crosslinked fibrin[J]. Biochimica et Biophysica Acta, 1973, 295（1）：308-313.
[25]Gaffney PJ. Distinction between fibrinogen and fibrin degradation products in plasma[J]. Clinica Chimica Acta, 1975, 65（1）：109-115.
[26]Gaffney PJ. D-dimer. History of the discovery, characterization and utility of this and other fibrin fragments[J]. Fibrinolysis, 1993, 7（2）：2-8.
[27]Franks JJ, Kirsch RE, Kao B, et al. Fibrinogen and fibrinogen-related peptides in cancer[J]. Pathophysiology of Plasma Protein Metabolism, 1984：265-278.
[28]Alwan A. Global status report on noncommunicable diseases 2010[R]. World Health Organization, 2011.
[29]Shackell LF. An improved method of desiccation, with some applications to biological problems[J]. American Journal of Physiology, 1909, 24（3）：325-340.
[30]Wang W. Lyophilization and development of solid protein pharmaceuticals[J]. International Journal of Pharmaceutics, 2000, 203（1）：1-60.